Many investors and analysts have increasingly lowered their expectations for the U.S. and China to find a quick resolution.World Economyread more
Billionaire investor Howard Marks, the co-chairman of Oaktree Capital, predicts there won't be a recession in the U.S. for another two years.US Economyread more
Network officials also said voters should expect more of a Koch focus on grassroots activism throughout the 2020 election cycle.Politicsread more
One person was killed and five others wounded on Thursday in a shooting on the streets of Washington, D.C., not far from the White House, police said.U.S. Newsread more
Stores are extending hours and cities are spending on light shows as China tries to encourage consumers to spend more money at night.China Economyread more
New research suggests fewer girls pursue careers in STEM — science, technology, engineering and math — because they're better than boys at reading.Closing The Gapread more
Stocks in Asia Pacific edged up in Friday afternoon trade as a series of developments overnight on the U.S.-China trade front dampened hopes of a deal being reached between...Asia Marketsread more
GM's usage of temporary workers, potential closure of plants and health care contributions remain major sticking points, according to people familiar with the talks.Autosread more
In a room full of avowed capitalists, policies that sound to some like socialism are bound not to go over well.Delivering Alpharead more
Trump has criticized Facebook numerous times since becoming president, most recently posting on Twitter that the company's proposed digital currency, libra, will "have little...Technologyread more
Republicans and Democrats have long since separated themselves by ideology, leaving each more uniformly conservative or liberal than ever. And now a new data analysis by the...Politicsread more
Botox may soon have a competitor that could last longer.
Revance Therapeutics' wrinkle-reducing injection met its goal of lasting for six months, according to phase three trial results the company released Tuesday. Competitors Allergan's Botox Cosmetic and Galderma's Dysport last up to four months, according to their websites.
Revance's RT002 uses the same active ingredient as its competitors, botulinum toxin Type A, but was created using the company's proprietary peptide technology. The product is 15 years in the making and is now one step closer to reaching consumers.
A long-term safety study is already underway and is expected to conclude in the second half of next year. Revance plans to bring the injection to market in 2020, assuming the drug receives approval from the Food and Drug Administration.
"We believe today's results not only validate the effectiveness and patient response but substantiate RT002 injectable's place as a distinctly new generation of long-acting neuromodulators," Revance co-founder and CEO Dan Browne said Tuesday on a call outlining the study's findings.
Allergan wasn't as impressed. In a statement, it called the results "underwhelming" and said it doesn't believe the data released Tuesday will support a claim that RT002 lasts longer.
The company's Botox injection was introduced for cosmetic use in 2002 and remains the market leader.
"Allergan continues to invest in neurotoxin research and development. The company's continued investment includes potential future indications for Botox and Botox Cosmetic as well as next-generation neurotoxins," the company said in an emailed statement.
Cantor Fitzgerald analyst Louise Chen said the data were "meaningfully better than expected by the Street" in a research note published Tuesday. Shares of Revance skyrocketed 33.7 percent Tuesday. They've now gained nearly 68 percent this year.
Allergan's stock, meanwhile, fell 1.5 percent and was trading at its lowest levels since December 2013. It has shed nearly 22 percent on the year.